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ARTICLE
Testosterone is an endogenous regulator of BAFF
and splenic B cell number
Anna S. Wilhelmson 1,2, Marta Lantero Rodriguez 1, Alexandra Stubelius3,4, Per Fogelstrand1,
Inger Johansson1, Matthew B. Buechler5, Steve Lianoglou5, Varun N. Kapoor5, Maria E. Johansson6,
Johan B. Fagman 7, Amanda Duhlin8, Prabhanshu Tripathi9, Alessandro Camponeschi10, Bo T. Porse 2,
Antonius G. Rolink11, Hans Nissbrandt12, Shannon J. Turley5, Hans Carlsten3, Inga-Lill Mårtensson10,
Mikael C.I. Karlsson 8 & Åsa Tivesten 1
Testosterone deﬁciency in men is associated with increased risk for autoimmunity and
increased B cell numbers through unknown mechanisms. Here we show that testosterone
regulates the cytokine BAFF, an essential survival factor for B cells. Male mice lacking the
androgen receptor have increased splenic B cell numbers, serum BAFF levels and splenic Baff
mRNA. Testosterone deﬁciency by castration causes expansion of BAFF-producing ﬁbro-
blastic reticular cells (FRCs) in spleen, which may be coupled to lower splenic noradrenaline
levels in castrated males, as an α-adrenergic agonist decreases splenic FRC number in vitro.
Antibody-mediated blockade of the BAFF receptor or treatment with the neurotoxin 6-
hydroxydopamine revert the increased splenic B cell numbers induced by castration. Among
healthy men, serum BAFF levels are higher in men with low testosterone. Our study uncovers
a previously unrecognized regulation of BAFF by testosterone and raises important questions
about BAFF in testosterone-mediated protection against autoimmunity.
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Sex steroid hormones have profound effects on the immunesystem, and insight into these effects may provide impor-tant clues to the sexual dimorphism of immune-dependent
disorders. Many autoimmune diseases, such as rheumatoid
arthritis and systemic lupus erythematosus (SLE), are less pre-
valent in men1 and data suggest that testosterone, the main
androgen, may protect against autoimmune disease1,2. Androgen
deﬁciency, resulting from various causes such as hypopituitarism
or Klinefelter´s syndrome, has been associated with increased risk
of female-predominant autoimmune diseases; the risk of SLE
increases 18-fold in Klinefelter patients and clinical remission has
been reported after testosterone substitution3. Testosterone deﬁ-
ciency induced by castration also increases disease activity in
mouse models of autoimmune disease such as experimental
autoimmune glomerulonephritis and lupus4,5, and androgen
treatment improves survival in male lupus NZB/NZW F1 mice6.
While the complex effects of oestrogens on adaptive immunity
have been extensively studied7, less is known about how andro-
gens modulate the immune system8. Patients with both hypo-
gonadotropic hypogonadism and Klinfelter´s syndrome have
higher blood B cell count, which is lowered by testosterone
replacement therapy9,10. Testosterone suppresses B lymphopoi-
esis in the bone marrow8, and we have shown that male general
androgen receptor (AR; the receptor for testosterone) knockout
(G-ARKO) mice have increased numbers of bone marrow B cell
precursors from the pro-B stage11. Through studies of osteoblast-
lineage cell-speciﬁc ARKO (O-ARKO) mice, we also could show
that the osteoblast-lineage cell is a likely target for these andro-
genic actions in the bone marrow11.
Testosterone and the AR also profoundly suppress splenic B
cell number in male mice and men8. Notably, while O-ARKO
mice mimic the bone marrow B cell pattern of G-ARKO, they
display unaltered numbers of mature B cells in the spleen11. The
regulation of splenic B cell number by testosterone may therefore
depend on a mechanism that acts independently of bone marrow
B lymphopoiesis. One candidate mechanism may involve
downregulation of the cytokine BAFF (also known as
TNFSF13B), an essential survival factor for splenic B cells that is
required for normal splenic B cell numbers12. BAFF deﬁciency in
mice results in an arrest at the transitional B cell stage in the
spleen13 and thus a lack of mature B cells. Further, BAFF is
implicated in autoimmunity, as excessive BAFF levels allow the
survival of autoreactive B cells and autoantibody production14.
Indeed, a variant in the BAFF gene has been coupled to soluble
BAFF levels, blood B cell levels, and increased risk of multiple
sclerosis and SLE15. BAFF inhibitors are approved as therapy for
SLE, although their clinical usefulness remains limited16.
In this study, we sought to deﬁne the mechanism by which
testosterone regulates splenic B cell number in males. We show
that testosterone is an endogenous regulator of BAFF. In line with
data coupling increased splenic noradrenaline levels to depressed
splenic B cell number and BAFF levels17,18, we further show that
this regulation may involve a testosterone-mediated increase in
sympathetic nervous transmission19–23. An expansion of BAFF-
producing ﬁbroblastic reticular cells (FRCs) in spleen after cas-
tration may be coupled to reduced splenic noradrenaline levels, as
an α-adrenergic agonist decreases FRC number in vitro. We
conclude that the link between testosterone deﬁciency and
increased splenic B cell numbers in males may involve nervous
regulation of FRCs and BAFF.
Results
Testosterone regulates splenic B cell number. First, we studied
splenic B cells in mice with a general deletion of the AR (G-
ARKO), where the Arﬂox construct was recombined upon
ubiquitous expression of Cre recombinase under control of the
phosphoglycerate kinase-1 (Pgk1) promoter24. As our initial
assessments showed no difference in androgen status (wet weight
of androgen-sensitive organs) and splenic B cell number between
Ar+ and Arﬂox male mice (Supplementary Fig. 1), Cre+ litter-
mates without the Arﬂox construct were used as controls. Male G-
ARKO mice had 1.8-fold more B cells in the spleen than litter-
mate controls (with the Pgk1-Cre construct only) (Fig. 1a, b). By
contrast, the number of dendritic cells, macrophages/monocytes
and neutrophils were unaltered in G-ARKO spleens (Supple-
mentary Fig. 2a–c).
G-ARKO mice are also testosterone-deﬁcient25. To distinguish
the importance of testosterone vs. AR deﬁciency in this model, we
treated castrated control and G-ARKO mice with a physiological
dose of testosterone and analysed the total number of splenic B
cells. Testosterone reduced the number of splenic B cells only in
the controls (Fig. 1c). Thus, this inhibitory effect is entirely AR-
dependent and is not mediated by other pathways, such as
conversion of testosterone to estradiol.
G-ARKO did not affect the relative number of peritoneal self-
renewing B1a and B1b B cells (Fig. 1d). However, the splenic
numbers of both transitional (T1, T2, T3) and mature marginal
zone and follicular B cells, as well as splenic B1 cells, were
increased (Fig. 1e–j). Further, G-ARKO males had a modest
increase in the relative number of B cells in blood (Supplementary
Fig. 2d).
In spleen sections from G-ARKO mice and controls (Fig. 1k),
the total number of B cell follicles was unaltered. However, G-
ARKO mice had larger follicular (Fig. 1l, m) and peri-arteriolar
lymphoid sheath (PALS) areas (Fig. 1n) than controls.
We also investigated whether G-ARKO mice had increased
concentrations of autoantibodies associated with autoimmune
disease26. Indeed, while total IgG levels were slightly reduced
(Fig. 1o), older G-ARKO mice had increased serum titres of IgG
anti-DNA antibodies (Fig. 1p).
Splenic mature B cell number is unaltered in O-ARKO mice.
An increased output of B cells from the bone marrow might
explain the increased splenic B cell pool in androgen/AR-deﬁcient
males. We have shown that osteoblast-lineage cell-speciﬁc (O-)
ARKO mice have alterations in bone marrow B cells similar to
those in G-ARKO mice11. Thus, osteoblast-lineage cells are likely
targets for androgen/AR-mediated inhibition of bone marrow B
lymphopoiesis. Analysis of the splenic B cell pool of O-ARKO
mice showed that the number of splenic transitional B cells was
also increased in O-ARKO mice, but to a lesser extent than in G-
ARKO mice (Fig. 2a, b). However, the mature B cell pool was not
increased (Fig. 2c, d). Thus, the increased number of mature B
cells in the spleen of G-ARKO mice is not explained by increased
B lymphopoiesis and must be driven by a peripheral mechanism.
Testosterone regulates the B cell survival factor BAFF. Since
BAFF is important for B cell survival12, we hypothesized that
testosterone negatively regulates BAFF. Indeed, serum BAFF
levels were higher in G-ARKO mice than in littermate controls
(Fig. 3a). Within 7 days after castration of male wildtype mice,
serum BAFF was higher than in sham-castrated controls (Fig. 3b),
illustrating the regulation of BAFF by endogenous testosterone. In
accordance, serum BAFF was higher in female mice compared to
male littermates (Fig. 3c).
Stromal cells in the spleen, in particular FRCs, are an
important source of BAFF27. Therefore, we investigated whether
testosterone regulates BAFF expression locally in the spleen.
Indeed, Tnfsf13b (Baff) mRNA in the spleen was increased in G-
ARKO mice (Fig. 3d). Further, a physiological testosterone
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replacement reduced spleen levels of Baff mRNA in castrated
control but not G-ARKO mice (Fig. 3e); thus, testosterone
downregulates splenic Baff mRNA in an AR-dependent manner.
Supporting a function of stromal cells, Baff mRNA expression
was not changed in sorted splenic B cells and other splenic
leucocytes after castration (Supplementary Fig. 3a, b). Immuno-
histochemical analysis revealed that BAFF-positive cells were
abundant and, as expected27, mainly located in the follicles
(Fig. 3f). Consistent with the Baff mRNA results and the
increased B cell numbers, the relative BAFF-positive area was
larger in G-ARKO mice (Fig. 3g).
Since BAFF signals through the BAFF receptor (BAFF-R) for
the survival of the pre-immune mature B cell pool27, we studied
the effect of castration on splenic B cell numbers during
treatment with a monoclonal antibody that inhibits binding to
the BAFF-R (9B9), or a control antibody (5A12)28. Although
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neither treatment affected transitional T1 B cells, 9B9 reduced the
effect of castration on T2 and T3 B cells (Fig. 3h–j) and blocked
the effect of castration on the number of mature splenic B cells
(Fig. 3k). This was not explained by altered Baffr (Tnfrsf13c)
mRNA expression in B cells of castrated mice (Supplementary
Fig. 3c). Thus, endogenous testosterone regulates mature splenic
B cell number by a BAFF-R-dependent mechanism.
To assess androgen-mediated regulation of BAFF in humans,
we measured serum BAFF levels in a population-based cohort of
160 healthy men 18–50 years of age. Twelve were biochemically
deﬁned as hypogonadal and 114 as eugonadal (Supplementary
Table 1); 34 did not meet the criteria for eu- or hypogonadism
and were excluded. Serum BAFF levels were signiﬁcantly higher
in the hypogonadal men (mean ± s.d., 968 ± 285 vs. 809 ± 229 pg/
ml; mean difference 160 pg/ml, 95% conﬁdence interval 20–300
pg/ml, P= 0.027 by linear regression; Fig. 3l). The difference
remained signiﬁcant after adjustment for age and body mass
index (P= 0.011 by linear regression). Thus, BAFF levels reﬂect
testosterone status in men.
AR regulation of splenic B cells is not B cell intrinsic. The AR is
expressed in B cells, and a B cell-intrinsic effect of the AR in the
regulation of splenic B cell number has been proposed29.
Therefore, we analysed splenic B cell number in two B cell-
speciﬁc AR knockout (B-ARKO) mouse models generated with B
cell-speciﬁc Cre constructs: Cd79a-Cre expressed in early pro-B
cells30 and Cd19-Cre expressed in pre-B cells31. Despite highly
efﬁcient deletion of AR in B cells, B cell numbers in the spleen
were unaltered in both models (Table 1).
Testosterone regulates splenic catecholamine levels. We next
assessed a possible connection to neuronal signalling, which
profoundly affects splenic homoeostasis32. Reduced splenic B cell
number and BAFF levels and increased splenic noradrenaline
levels have been reported after thoracic spinal cord injury17,18. Of
note, testosterone increases sympathetic nervous signalling19–23,
and noradrenaline and dopamine levels in the spleen were lower
in castrated males than in sham-operated controls (Fig. 4a, b).
Accordingly, immunohistochemical analysis of G-ARKO spleen
sections (Fig. 4c–e) showed reduced staining of tyrosine
hydroxylase-positive nerve ﬁbres in the white pulp of G-ARKO
mice (Fig. 4c).
Notably, we observed proximity between nerve ﬁbres and
smooth muscle actin (SMA)-positive33 FRC reticulum in the
central parts of the follicles (Fig. 4g), where BAFF-staining was
intense (Fig. 4f). Thus, there are anatomical prerequisites for the
interaction between neuron-derived adrenergic neurotransmitters
and BAFF-producing stromal cells27.
Expansion of FRCs in testosterone or AR deﬁciency. Because
the central part of the follicle (i.e., the T cell zone or PALS area) is
enriched in nerves, BAFF and BAFF-producing FRCs, we
examined this area more closely. Although G-ARKO spleens had
enlarged PALS areas (Fig. 1n), the T cell numbers were, in
comparison, modestly higher (CD4 T cells: 20 ± 0.8 × 106 in G-
ARKO vs. 14 ± 0.5 × 106 in controls, P < 0.001; CD8 T cells: 12 ±
0.5 × 106 vs. 9.2 ± 0.4 × 106, P < 0.001 by Mann–Whitney test).
Since CD4+ T cells may relay neural signals to other immune
cells along the “cholinergic anti-inﬂammatory pathway”34, we
assessed the importance of T cells in the effect of castration on the
splenic B cell population. In mice castrated before puberty,
treatment with a T cell-depleting antibody regimen (anti-CD3)
reduced the number of splenic CD4+ T cells by 50% (Supple-
mentary Fig. 4a); however, the effect of castration on splenic B
cells was unaltered (Supplementary Fig. 4b), arguing against a
central function for T cells.
We next asked whether the expansion of the PALS area was
associated with expansion of the SMA-positive33 stromal FRC
compartment. Indeed, even in relation to the total PALS area, the
SMA-positive area was increased in the PALS of G-ARKO mice
(Fig. 5a, b). To validate the latter ﬁndings, we analysed splenic
stromal cells by FACS shortly after castration (Fig. 5c). The total
number of CD45− cells was unchanged in castrated mice
(Fig. 5d), but the FRC population, deﬁned as CD45–CD31–
PDPN+ cells, was expanded in castrated mice (Fig. 5e, f). No
similar effect was observed in inguinal lymph nodes, although
these had a modest increase in B cell numbers (Supplementary
Fig. 5a, b). Thus, stromal cells with BAFF-producing capacity
expanded in the spleen after castration.
Splenic FRCs express α-adrenergic receptors. Given the proxi-
mity between nerve ﬁbres and FRC reticulum, we next tested the
hypothesis that catecholamines regulate the FRC compartment.
To determine whether splenic FRCs express adrenergic receptors,
we sorted splenic FRCs by FACS (Supplementary Fig. 6a, b). Our
sample replicates were consistent across sorts and suggested
ﬁdelity of our sequencing data, as shown by pairs plots (Sup-
plementary Fig. 6c). Moreover, the high levels of genes associated
with ﬁbroblastic function, including Col1a1, Col1a2, Fbn1 and
Fn1 and low expression of haematopoietic (Ptprc; CD45) and
endothelial (Epcam) genes (Supplementary Fig. 6d), showed that
these cells were ﬁbroblasts. Robust expression of classical FRC
genes such as Ccl19, Ccl21a, Cxcl13 and Tnfsf13b (Baff) suggested
these were bona ﬁde splenic FRC (Supplementary Fig. 6d).
Within the adrenergic receptor family, Adra1b, Adra2b and
Adrb2 were expressed at more than one transcript per million
(Fig. 6a). Other α- and β-adrenergic and dopaminergic receptors
were found at lower levels and therefore were not likely expressed
(Fig. 6a). To conﬁrm α-adrenergic receptor expression at the
protein level, we analysed splenic FRCs by FACS (Fig. 6b). This
analysis showed that 18% (ADRA1B) and 95% (ADRA2B) of
Fig. 1 Testosterone regulates splenic B cell number. a Representative plots of CD19+CD93+ transitional B cells (tB) and CD19+CD93– mature B cells
(matB) in the spleen from male control (Pgk-Cre+) and general androgen receptor knockout (G-ARKO) mice. b Total CD19+ B cells in the spleen in control
(n= 10) and G-ARKO (n= 9) mice. c Total CD19+ B cells in the spleen in castrated (ORX) control and G-ARKO male mice treated with placebo (P) or
testosterone (T) (25 μg/day) for 4 weeks (Control ORX P, n= 6; Control ORX T, n= 7; G-ARKO ORX P, n= 5; G-ARKO ORX T, n= 6; P-value from
Kruskal–Wallis test followed by Mann–Whitney test). d % B1a (CD19+IgM+CD43+CD5+) and B1b (CD19+ IgM+CD43+CD5–) cells in peritoneal ﬂuid
from control and G-ARKO male mice, n= 9/group. e–j CD19+ B cells were divided into subpopulations; graphs show transitional T1 (CD19+CD93+IgM
+CD23–) B cells (e), transitional T2 (CD19+CD93+IgMhiCD23+) B cells (f), transitional T3 (CD19+CD93+IgMloCD23+) B cells (g), follicular (FO) (CD19
+CD93+CD21intCD23+) B cells (h), marginal zone (MZ) (CD19+CD93+CD21hiCD23–) B cells (i), and B1 (CD19+CD43+) B cells (j) in the spleen in control
(n= 10) and G-ARKO (n= 9) mice. k Sections of spleens from control and G-ARKO male mice. green, B cells (B220); red, T cells (TCRβ); and blue,
metallophilic macrophages (MOMA/CD169). Scale bar= 500 μm. l–n Number of follicles per section (l) and mean B cell area (m) and mean PALS area
(n) per follicle in spleen sections from control and G-ARKO mice, n= 4/group. o Total IgG levels in serum from control (n= 22) and G-ARKO (n= 19)
mice. p IgG autoantibodies against DNA in control (n= 23) and G-ARKO (n= 18) mice. All bars indicate means; circles represent individual mice. *P <
0.05, **P < 0.01, ***P < 0.001 (Mann–Whitney test unless otherwise speciﬁed)
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splenic CD45–CD31–PDPN+ cells stained positive for receptor
expression.
α-Adrenergic manipulation regulates FRC numbers in vitro.
We next set up an in vitro system to culture splenic primary
stromal cells, including enrichment for CD45– and CD31– stro-
mal cells35 (Supplementary Fig. 7). Exposure of the enriched cells
to the α- adrenergic agonist phenylephrine for 48 h reduced the
number of stromal cells in a dose-dependent manner (Fig. 6c).
Concomitant treatment with the α-adrenergic blocker phentola-
mine increased the number of cells in a dose-dependent manner
(Fig. 6c). Signs of cell apoptosis were similar in the treatment
groups (Fig. 6d). However, in a carboxyﬂuorescein succinimidyl
ester (CFSE) assay, phenylephrine-treated cells had reduced
proliferation, which was partly reversed by phentolamine
(Fig. 6e). We conﬁrmed that phenylephrine reduced the number
of PDPN+ cells in culture and that this effect was antagonized by
phentolamine (Fig. 6f, g). Thus, α-adrenergic stimulation of
splenic stroma in vitro reduces the number of FRCs (CD45–
CD31–PDPN+ stromal cells), and this effect is antagonized by an
α-adrenergic blocker.
Testosterone effects on splenic B cells needs neurons. Our
ﬁndings raise the question of whether interference with neuro-
transmission would alter the effect of castration on splenic B cell
number and Baff mRNA. To test this possibility, we analysed the
castration response in mice treated with 6-hydroxydopamine (6-
OHDA)36, which is toxic to adrenergic neurons. In saline-treated
controls, the numbers of mature B cells increased in response to
castration, as expected (Fig. 6h); however, 6-OHDA completely
blocked this effect (Fig. 6h). Further, 6-OHDA reduced Baff
mRNA and blocked the castration response of Baff mRNA in the
spleen (Fig. 6i). These data show that intactness of adrenergic
neurons is required for testosterone’s effects on splenic B cell
number and Baff mRNA levels.
Discussion
Here we show that testosterone is an endogenous regulator of
BAFF and propose that the link between testosterone deﬁciency
and increased splenic B cell numbers in males involves nervous
regulation of FRCs and BAFF.
Consistent with the notion that a deﬁciency in androgens and/
or the AR increases splenic B cell number8, both G-ARKO and
castrated mice had an increased number of B cells in spleen.
Short-term castration of adult mice resulted in a doubling of the
number of splenic B cells, similarly to G-ARKO mice in which the
AR deletion is present from embryonic stage24, suggesting that
the regulation of splenic B cell number by testosterone/AR occurs
independently of developmental effects. Our ﬁndings in O-ARKO
mice did not support increased bone marrow B lymphopoiesis as
a major underlying mechanism; however, we found that testos-
terone regulates the B cell survival factor BAFF and that BAFF-R
blockade prevented the effect of castration on mature B cell
number in the spleen. Moreover, serum BAFF levels were con-
sistently increased in hypogonadal young men, a ﬁnding sup-
ported by negative correlation between serum BAFF and
testosterone levels in men with psoriatic arthritis37.
In our study, BAFF levels were modestly increased by testos-
terone/AR deﬁciency. There are no data available on the
concentration-response relation between local or systemic BAFF
levels and B cell numbers in mice. BAFF overexpression and
knockout are both extreme models, which do not contribute to
this knowledge. There are small biological variations in BAFF
levels in homoeostasis, which may be concordant with a tight
regulation of BAFF and that even small alterations may change B
cell homoeostasis. This notion is supported by human data,
suggesting that serum BAFF levels within normal ranges are
inversely associated with peripheral B cell numbers38,39. Further,
healthy subjects heterozygous for the BAFF variant that has been
associated with clinical autoimmune disease have a modest
21–23% increase in serum BAFF levels15.
In the present study, castration’s effect on mature splenic B cell
number was prevented by concomitant treatment with a blocking
BAFF receptor antibody, supporting that endogenous testoster-
one regulates mature splenic B cell number in a BAFF-R-
dependent manner. The intact effect of castration on splenic
transitional T1 B cell number during BAFF-R blockade may
reﬂect an intact, BAFF-independent40 increase in the inﬂux of
early transitional B cells from the bone marrow to the spleen,
corresponding to the increase in early transitional B cells in the
spleens of O-ARKO mice11. Combined, these two distinctly
regulated actions in bone marrow and spleen may explain why all
splenic B cell subsets were increased in G-ARKO mice, but only
T2 and mature B, but not T1, cells were increased in mice
overexpressing BAFF12,40.
We found here that both noradrenaline and dopamine con-
centrations in the spleen were lower in castrated male mice than
in sham-operated controls. These ﬁndings are in line with the
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reduced catecholamine levels in, for example, the hearts of
androgen-deﬁcient male mice and men22,23 and the reduced
tyrosine hydroxylase activity in sympathetic ganglia after castra-
tion21. Testosterone increases sympathetic nervous signalling19–23
and likely does so at different levels: from the brain to direct
modulation of autonomous reﬂex pathways. Studies that
attempted to decipher the effects of testosterone on pelvic
autonomous pathways illustrate the complexity of this modula-
tion19. These studies also show that testosterone affects nora-
drenaline levels not only in reproductive organs but also in other
visceral organs19, although such effects in the spleen have not
been described previously.
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The fact that neuronal signalling has profound effects on
splenic homoeostasis32 is well accepted; for example, by the early
1980s noradrenaline from sympathetic nerve terminals was
known to negatively regulate antibody responses in the spleen41.
However, previous research mainly focused on immune cells,
rather than stromal cells, as direct targets of neurotransmitters41.
Here we found that splenic FRCs express α-adrenergic receptors
and that exposure of primary splenic stromal cells to an
α-adrenergic agonist reduces the expansion of these cells in vitro.
Accordingly, spleens from castrated mice had low noradrenaline
levels and an increased number of FRCs. To our knowledge, the
regulation of FRCs or other splenic stromal cells by adrenergic
transmitters has not been investigated previously. Outside the
immune system, adrenergic regulation of ﬁbroblastic cells is
important in the heart42 and lung43, and the sympathetic nervous
system regulates the proliferation of perivascular stromal cells in
the bone marrow44.
A function of the stroma in autoimmune diseases, such as
Sjögren´s syndrome and rheumatoid arthritis, is increasingly
recognized45. In primary Sjögren's syndrome, the local formation
of tertiary lymphoid structures (TLS) associates with a negative
prognosis. TLS contain networks of stromal cells resembling
those of secondary lymphoid organs and local BAFF production
is associated with resistance to B cell depletion and loss of clinical
response46. An important question raised by our ﬁndings is
whether stromal cells of TLS in Sjögren´s syndrome and other
autoimmune disorders may be regulated directly by the adre-
nergic nervous system.
Our ﬁndings suggest that the link between testosterone/AR
deﬁciency and increased BAFF production involves regulation of
sympathetic neuronal activity by testosterone and the AR, likely
at multiple levels in the autonomous nervous system, resulting in
lower noradrenaline levels in the spleen. Noradrenaline mediates
the reduction of FRC number through α-adrenergic receptor
expression on FRCs. Thus, the decreased splenic noradrenaline
levels in testosterone/AR deﬁciency increases the number of
FRCs. Since BAFF production in secondary lymphoid organs
relies heavily on the FRC stromal compartment47, these events
provide a mechanism for the increased splenic production of
BAFF in testosterone/AR deﬁciency. The increase in B cell
number in the lymph nodes was less pronounced than in the
spleen, and not associated with increased FRC number, suggest-
ing that this is a systemic effect of BAFF. Overall, our ﬁndings are
consistent with recent results of depressed splenic B cell number
and BAFF levels, in conjunction with increased splenic nora-
drenaline levels, after higher, but not lower, thoracic spinal cord
injury17,18.
While we suggest that testosterone regulates BAFF and splenic
B cell number in an AR-dependent manner, the functional rele-
vance of this regulation for antibody-mediated diseases remains
unclear. G-ARKO mice displayed increased anti-DNA antibodies
that may be associated with autoimmune disease26, but we have
not studied disease development in G-ARKO or castrated mice.
However, castration has previously been shown to aggravate
disease in different animal models of autoimmune disease, such
as experimental lupus and arthritis models4–6,48–51. Further,
treatment with both testosterone and the endogenous AR agonist
dihydrotestosterone ameliorates experimental lupus and
arthritis6,48–50, supporting a protective effect of AR activation.
Importantly, while BAFF inhibition may be protective in
experimental lupus models52,53, the importance of BAFF reg-
ulation for the beneﬁcial effects of testosterone/AR agonist in
experimental disease models remains unclear. Once the AR target
cell for BAFF regulation is identiﬁed, a knockout of the AR
speciﬁcally in this cell type may be a useful approach to address if
AR signalling affects autoimmunity via BAFF regulation.
In accordance with the lower prevalence of autoimmune dis-
eases in men, it has been proposed that estradiol accelerates and
testosterone inhibits autoimmunity1. Interestingly, both hor-
mones suppress bone marrow B lymphopoiesis11,54 but differ in
their effects on splenic B cell number and BAFF. In the present
study, we found that serum BAFF levels were higher in female
compared to male mice, which is in accordance with a previous
report of sex differences in BAFF levels among wild-type con-
trols55. We further found that testosterone suppresses BAFF, and
others have shown that estradiol increases Baff mRNA levels and
the relative number of mature B cells in the spleen54. Hence,
estradiol elevates BAFF production and accelerates autoimmune
disease1,54, whereas testosterone has the opposite effects8. Like
testosterone, estradiol has complex actions on autonomic neu-
roeffector mechanisms, but its net effect is likely reduced per-
ipheral sympathetic nerve activity56. Therefore, differences in the
regulation of BAFF by estradiol and testosterone, potentially
driven by nervous mechanisms, may contribute to the sex dif-
ference in autoimmune diseases in which BAFF has a pathogenic
function.
In conclusion, our study uncovers a previously unrecognized
regulation of BAFF by testosterone. Our data raise important
questions about BAFF in testosterone-mediated protection
against autoimmunity as well as the sexual dimorphism in
autoimmune disorders.
Methods
Animals and study design. Male mice with a general depletion of the AR from the
embryonic stage (G-ARKO)24 were generated by breeding Ar+/ﬂox females24 with
males expressing Cre recombinase ubiquitously under the control of the Pgk1
promoter24,25. Osteoblast-lineage cell-speciﬁc (O-ARKO)11 and B cell-speciﬁc (B-
ARKO) ARKO mice were generated by breeding Ar+/ﬂox females with Osx1-Cre+
males (Tg(Sp7-tTA,tetO-EGFP/cre)1Amc, Jackson Laboratory) to produce O-
ARKO, Cd79a-Cre+ mice (also called Mb1-Cre+; from Prof. Michael Reth)30 or
with Cd19-Cre+ mice (B6.129P2(C)-Cd19tm1(cre)Cgn/J, Jackson Laboratories) to
produce B-ARKO mice. Ar, Cre, and Zfy (for gender) expression was assessed by
PCR ampliﬁcation of genomic DNA (primer sequences in Supplementary Table 2).
In all experiments, mice were compared to littermate controls; all mice were on
Fig. 3 Testosterone regulates the B cell survival factor BAFF. a Serum BAFF level in control (Pgk-Cre+) and general androgen receptor knockout (G-ARKO)
male mice, n= 10/group. b Serum BAFF level in castrated (ORX) and sham-operated male mice 7 days after surgery, n= 6/group. c Serum levels of BAFF
in serum from male (n= 19) and female (n= 18) 12-week-old littermate wild-type mice. d BaffmRNA expression in the spleen in control and G-ARKO male
mice, n= 10/group. e Baff mRNA expression in the spleen from castrated (ORX) control and G-ARKO male mice treated with placebo (P) or testosterone
(T) (25 μg/day) for 4 weeks (Control ORX P, n= 12; Control ORX T, n= 12; G-ARKO ORX P, n= 10; G-ARKO ORX T, n= 13; P-value from Kruskal–Wallis
test followed by Mann–Whitney test). f Sections of spleens from control and G-ARKO male mice. Green, BAFF staining. Scale bar, 500 μm. g Quantiﬁcation
of BAFF-stained area/total area of spleen section, n= 6/group. h–k Transitional T1 (CD19+CD93+IgM+CD23–) B cells (h), transitional T2 (CD19+CD93
+IgMhiCD23+) B cells (i), transitional T3 (CD19+CD93+IgMloCD23+) B cells (j) and mature B cells (matB) (CD19+CD93–) (k) in spleens of castrated
(ORX) or sham-operated male mice treated with a BAFF-R blocking (9B9) or control (5A12) antibody (Sham 5A12, n= 7; ORX 5A12, n= 7; Sham 9B9, n=
7; ORX 9B9, n= 8; P-value from Kruskal–Wallis test followed by Mann–Whitney test). a–k Bars indicate means; circles represent individual mice. *P < 0.05,
**P < 0.01 and ***P < 0.001 (Mann–Whitney test unless otherwise speciﬁed). l Serum BAFF levels in healthy young men biochemically deﬁned as
eugonadal (total testosterone > 13 nmol/l and free testosterone > 0.22 nmol/l; n= 114) or hypogonadal (total testosterone < 13 nmol/l and free
testosterone < 0.22 nmol/l; n= 12). Data are presented as a box plot (25th–75th percentile). Horizontal bars represent median values and whiskers
represent minimum and maximum values. *P < 0.05 (linear regression)
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C57BL/6J background, unless otherwise stated. The mice were housed in speciﬁc
pathogen-free facility, in a temperature- and humidity-controlled room with a
06:00–18:00 h light cycle and fed a soy-free diet (R70, Lantmännen) and tap water
ad libitum. All animal studies were approved by the Ethics Committee on Animal
Care and Use in Gothenburg or at Genentech and were in accordance with the
NIH “Guide for the Care and Use of Laboratory Animals” (8th ed. The National
Academies Press. 2011).
Orchiectomy and testosterone treatment. Four weeks before tissue collection, 8-
week-old G-ARKO and littermate controls were bilaterally orchiectomized or
sham-operated and implanted subcutaneously with a small slow-release pellet
containing placebo or a physiological dose25 of testosterone (25 µg/day; Innovative
Research of America). In separate experiments, male wild-type mice were sham-
operated or orchiectomized 7–14 days before tissue collection.
Treatment with BAFF-R blocking antibody. Twelve-week-old male wild-type
mice were bilaterally orchiectomized or sham-operated and given a single intra-
venous injection (0.5 mg) of a monoclonal BAFF-R blocking antibody (9B9) or a
control non-blocking antibody (5A12), both provided by Prof. Rolink28. Spleens
were collected 2 weeks later. Previous studies have shown that B cell reduction by
9B9 is neither due to antibody-dependent cellular cytotoxicity nor to complement-
mediated lysis28.
T cell depletion. At 4 weeks of age, male mice (B6.129P2-Apoetm1Unc; Taconic)
were bilaterally orchiectomized or sham-operated. One week later, the mice
received an intraperitoneal injection (50 μg) of monoclonal anti-mouse CD3
antibody (145-2C11 f(ab′)2 Fragments; BioXCell) or a control antibody (Hamster
IgG f(ab′)2 Fragments; BioXCell) on 5 consecutive days. The injections were
repeated at 3-week intervals (when the mice were 5, 8, 11 and 14 weeks old).
Spleens were collected at 16 weeks of age.
Treatment with 6-hydroxydopamine. Eight-week-old male wild-type mice were
bilaterally orchiectomized or sham-operated and treated with a single intraper-
itoneal injection of 6-hydroxydopamine (250 mg/kg; Sigma Aldrich) or saline36.
Tissues were collected 2 weeks later.
Tissue collection and cell isolation. All mice were killed at 10–14 weeks of age
(unless otherwise speciﬁed). The mice were anaesthetized (Isoﬂo vet; Orion
Pharma Animal Health), blood was drawn from the left ventricle and the mice were
perfused with saline at physiological pressure (around 110 mmHg) for 5 min. Cells
from the peritoneal cavity were isolated by lavage and kept in phosphate-buffered
saline (PBS) on ice. After dissection, tissues were snap-frozen in liquid nitrogen for
DNA and RNA quantiﬁcation, frozen for cryosectioning (Cryomount, Histolab
Products) or kept in PBS on ice for cell isolation.
Preparation of cells for ﬂow cytometry. To obtain single cells, spleen and
inguinal lymph nodes were directly passed through a nylon wool sieve (70 µm). To
obtain stromal cells, the spleen and inguinal lymph nodes were minced and
enzymatically digested, as described35. Erythrocytes (in spleen) were haemolysed
(0.16 M NH4Cl, 0.13 M EDTA and 12 mM NaHCO3 in H2O or ACK lysis buffer),
and the cells were washed in ﬂow cytometry buffer (2% foetal bovine serum and 2
mM EDTA in PBS), ﬁltered through a 70 µm cell strainer and counted in an
automated cell counter (Sysmex or ViCell). After Fc-blockage (anti-mouse CD16/
CD32, clone 2.4G2, BD Biosciences), expression of various cell-surface markers was
detected with ﬂuorochrome-conjugated antibodies: CD19 (1D3; BD Biosciences),
CD93 (AA4.1; eBioscience), IgM (Polyclonal; SouthernBiotech), CD23 (B3B4; BD
Biosciences), CD21 (7G6; BD Biosciences), CD43 (S7; BD Biosciences), CD11c
(N418; Biolegend), CD11b (M1/70; BD Biosciences), F4/80 (BM8; Biolegend), Gr1
(RB6-8C5; eBioscience), CD45 (30-F11; BioLegend), CD31 (390; BioLegend),
podoplanin (8.1.1; BioLegend), Pdgfrα (AP5; Biolegend), rabbit anti-α1b adre-
nergic receptor (EPR10336; Abcam), rabbit anti-α2b adrenergic receptor
(EPR9623; Abcam), rabbit IgG monoclonal isotype control (EPR25A; Abcam), F
(ab′)2 fragment donkey anti-rabbit IgG (H+ L) Alexa Fluor 647 (711-606-152;
Jackson ImmunoResearch). For exclusion of nonviable cells after enzymatic
digestion, LIVE/DEAD Fixable Aqua Dead Cell stain (Molecular Probes) was
added.
Peritoneal cells were isolated by lavage and washed with PBS. Expression of cell-
surface markers was detected with ﬂuorochrome-conjugated antibodies after Fc-
blockage (anti-mouse CD16/CD32; BD Biosciences): CD19 (1D3; BD Biosciences),
IgM (Polyclonal; SouthernBiotech), CD43 (S7; BD Biosciences), and CD5 (53-7.3;
BD Biosciences).
Blood was drawn from the left ventricle and prevented from clotting by storage
in EDTA-coated microvette tubes (20.1288; Sarstedt). Leucocytes were enriched by
haemolysis of erythrocytes and the cells were washed in ﬂow cytometry buffer.
After Fc-blockage, expression of CD19 cell-surface marker was detected with a
ﬂuorochrome-conjugated antibody, as described above.
Fluorochrome-minus-one was used as control in all ﬂow cytometry
experiments. Cells were analysed with a FACS Canto II, LSRII, FACS Aria, or
Accuri C6 (all BD Biosciences); the data were further analysed with FlowJo
software (Tree Star). Cells were sorted directly into Trizol (Thermoﬁsher) after a
purity check on a FACS Aria or FACS Fusion (BD Biosciences).
The gating strategies for splenic B cells (Supplementary Fig. 8a), peritoneal B
cells (Supplementary Fig. 8b), and splenic FRCs (Supplementary Fig. 8c) are
described in the Online Supplement.
Sorting of splenic leucocytes. From isolated splenic cells, B cells were sorted
using anti-mouse CD19-conjugated magnetic microbeads (#130-052-201; Miltenyi
Biotec), according to the manufacturer's instructions. From the CD19− fraction
CD45+ leucocytes were isolated using anti-mouse CD45-conjugated magnetic
microbeads (#130-052-301; Miltenyi Biotec).
Antibodies in serum. Serum antibody levels were measured in 34-week-old G-
ARKO and control mice by enzyme-linked immunosorbent assay (ELISA)57. For
total IgG, ELISA plates were coated with anti-Ig (H+ L)(ASB-103101, Nordic
Biosite). Puriﬁed mouse IgG (0107-01, SouthernBiotech) was used as standard to
allow exact calculation of IgG levels. For anti-DNA IgG, ELISA plates were pre-
coated with methylated bovine serum albumin and calf thymus DNA (Sigma-
Aldrich). The antibody reactivity in serum was measured with an alkaline
phosphatase-conjugated anti-mouse IgG antibody (1030-04; SouthernBiotech). The
serum was serially diluted; for total IgG we present data at dilution 1:250,000 and
for anti-DNA IgG at 1:50. All samples were run in duplicate and corrected for
background binding.
Spleen immunohistochemistry. Cryosections (10 μm) of spleen were air dried for
2 h and stored at –20 °C. For immunolabelling, sections were ﬁxed for 5 min with
2% formaldehyde, permeabilized with 0.1% Triton-X for 4 min, treated with Avi-
din/Biotin Blocking Kit (Cat# BC-AB972; BioCare Medical), and incubated with
1% bovine serum albumin in PBS for 15 min before addition of primary antibodies.
PBS was used for all washes throughout the immunolabelling procedures except for
the last wash before mounting, which was done in deionized water. Spleen tissue
sections were incubated with rat anti-mouse CD169 (3D6.112; AbD Serotec; 1:100)
overnight at 4 °C and then with F(ab)2 AF594-conjugated donkey anti-rat IgG
(Jackson ImmunoResearch; 1:400) for 45 min at 20 °C. To block unspeciﬁc binding
of the anti-rat secondary antibodies, the sections were incubated for 15 min with
nonspeciﬁc rat IgG2a (R35-95; BD Biosciences; 1:30). The sections were then
incubated with AF488-conjugated rat anti-human/mouse B220 (RA3-6B2; Affy-
metrix; 1:100) and biotinylated hamster anti-mouse TCRβ (H57-597; Affymetrix;
1:100) for 60 min at 20 °C and with Atto425-conjugated streptavidin (ATTO-TEC;
1:200) for 30 min and mounted with ProlongGold mounting medium (Life
Technologies). In a similar protocol, sections were blocked in 1% bovine serum
albumin together with Fc-receptor blockage (anti-mouse CD16/32, 2.4G2; BD
Biosciences; 1:100) and incubated overnight with rat anti-mouse BAFF-AF488
(121808; R&D Systems; 1:20), rat anti-mouse IgD-biotin (11-26; SouthernBiotech;
1:150), mouse anti-smooth muscle alpha actin-Cy3 (1A4; Sigma Aldrich; 1:4000),
and rabbit anti-mouse tyrosine hydroxylase (cat no. ab112; Abcam; 1:300). Sections
were then incubated for 1 h with donkey anti-rabbit-AF647 (Jackson Immunor-
esearch; 1:300) and streptavidin-BV480 (BD Biosciences; 1:200). The number of
follicles per section and areas of B cell staining were quantiﬁed by computerized
Table 1 AR regulation of splenic B cells is not B cell-intrinsic
Target cell (Cre promoter) Mean reduction of Ar exon 2 DNA in B cells P-value No. of B cells (×106) P-value
Controls B-ARKO mice
B cells (Cd79a) 93% <0.0001 24 ± 4 20 ± 2 0.35
B cells (Cd19) 86% <0.0001 20 ± 3 20 ± 2 0.88
Presentation of B cell-speciﬁc ARKO model, Cre promoter used, AR knockout level in the model (measured as relative level of Ar exon 2 DNA in the B cell compartment), and total number of CD19+ B
cells in spleen in male control and B cell-speciﬁc ARKO (B-ARKO) mice. n= 11 and 8 (Cd79a-Cre+ controls and corresponding B-ARKO), n= 10 and 11 (Cd19-Cre+ controls and corresponding B-ARKO).
Values represent mean ± s.e.m. P-values from Mann–Whitney test.
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Fig. 4 Testosterone regulates splenic catecholamine levels. a Noradrenaline and b dopamine concentration in spleens of castrated (ORX; n= 6) and sham-
operated (n= 5) male mice. c Quantiﬁcation of tyrosine hydroxylase (TH)-stained area in control (Pgk-Cre+) and general androgen receptor knockout (G-
ARKO) male mice, expressed as percentage of follicle area. n= 7/group. d–f Sections of spleens from control and G-ARKO mice. Turquoise, nerve
structures (tyrosine hydroxylase; TH); red, ﬁbroblastic reticular cells (FRCs) and vascular structures (smooth muscle a-actin; SMA). B cells (IgD) are
stained white in e and BAFF is stained white in f. Scale bar, 100 μm. g Higher-magniﬁcation image of SMA-positive FRC (red) and TH-stained nerve
structures (turquoise); asterisk indicates area of co-localization. Scale bar, 20 μm. Bars indicate means; circles represent individual mice. *P < 0.05
(Mann–Whitney test)
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colour selection (BioPix iQ 2.2.1); the BAFF immune-labelled area was quantiﬁed
by Visiopharm image analysis (version 4.6.3.857; Visiopharm).
DNA quantiﬁcation. Since exon 2 of the Ar gene is excised in the ARKO mouse
model24, we quantiﬁed exon 2 by using exon 3 as a reference to assess the efﬁcacy
of the cell-speciﬁc knockouts. For this purpose, CD19+ cells were isolated by
positive selection with Macs CD19 microbeads (Miltenyi Biotec). Genomic DNA
from CD19+ cells, and organs/tissues was isolated with the DNeasy blood and
tissue kit (Cat#69504; Qiagen) according to the manufacturer’s instructions.
Ampliﬁcation of genomic DNA was detected with SyBR green master mix
(Cat#4367659; Thermoﬁsher Scientiﬁc) and an ABI Prism 7900HT Sequence
Detection System (Applied Biosystems). The following primer pairs were used: Ar
exon 2: forward GGACCATGTTTTACCCATCG and reverse CCACAAGTGA-
GAGCTCCGTA; and Ar exon 3: forward TCTATGTGCCAGCAGAAACG and
reverse CCCAGAGTCATCCCTGCTT. Ct values for Ar exon 2 were normalized to
Ct values for Ar exon 3 by the 2−ΔΔct method.
Serum BAFF in mice and healthy men. Circulating BAFF concentrations in
mouse serum (diluted 1:6) were determined with a Quantikine ELISA (MBLYS0,
R&D Systems) according to the manufacturer's instructions.
In an observational study, fasting serum samples were obtained before 10 a.m.
from the control cohort of a study on subfertility in men58. This group of control
men (18–50 years old at inclusion) was selected from the Swedish Population
Register. None of the participants reported any serious medical problems, and none
were receiving fertility treatment, anti-diabetic/insulin therapy, opioids, or
glucocorticoids or other anti-inﬂammatory drugs. The study was approved by the
Regional Ethical Review Board at Lund University, Sweden. All subjects gave
written informed consent. Serum for assessment of serum testosterone and BAFF
was available for 160 men. Serum testosterone and free testosterone were assessed
as described58. BAFF concentrations in human serum (diluted 1:2) were
determined with a Quantikine ELISA (DBLYS0B R&D Systems). Hypogonadism
was biochemically deﬁned as total testosterone <13.0 nmol/l plus free testosterone
<0.22 nmol/l59. Eugonadism was deﬁned as total testosterone >13.0 nmol/l plus free
testosterone >0.22 nmol/l.
RNA isolation and real-time RT-PCR. Total RNA was extracted from spleen or
isolated spleen cells with the RNeasy Mini Kit (Cat#74104; Qiagen) according to
the manufacturer’s instructions. To eliminate DNA contamination, a DNase I
(Qiagen) step was included. Complementary DNA was synthesized from total RNA
with a high-capacity cDNA reverse transcription kit (Cat#4374966; Applied Bio-
systems). RT-PCR analysis was done with predesigned TaqMan Gene Expression
Assays (Applied Biosystems): Tnfsf13b (Baff; Mm00446347_m1) or Tnfrsf13c
(Baffr; Mm00840578_g1) (FAM) with Hprt (Mm00446968_m1, VIC) as a reference
gene. The analyses were run in an ABI Prism 7900HT Sequence Detection System
or a ViiA 7 (Applied Biosystems). Data were normalized to the reference gene, and
gene expression was calculated with the 2−ΔΔct method.
Measurement of splenic catecholamines. Noradrenaline and dopamine levels in
the spleen were determined by high-performance liquid chromatography followed
by electrochemical detection. Spleens in a solution of 0.1 M perchloric acid, 5.37
mM EDTA, and 0.65 mM glutathione were homogenized with a Branson Soniﬁer
450 (Branson Sonic Power). After centrifugation (10,000 × g, 5 °C, 10 min), the
supernatant was collected and immediately analysed for dopamine and nora-
drenaline. The amines were chromatographed on an ion-exchange column (EC
150/2 Nucleosil 100-5 SA, Macherey-Nagel) with a mobile phase consisting of 13.3
g of citric acid, 5.84 g of NaOH, 40 mg of EDTA, and 200 ml of methanol in
distilled water to a total volume of 1000 ml. Dopamine and noradrenaline were
detected at a 0.55 V oxidizing potential with a Waters 460 detector (Millipore
Waters, Milford). The resulting currents were acquired and integrated with
Chromeleon software (Thermoﬁsher Scientiﬁc).
RNAseq and bioinformatic analysis. Male C57BL/6 mice 7–9 weeks old (Jackson
Laboratories) were used for RNAseq experiments. For splenic FRC ex vivo quan-
tiﬁcation, 6–8-week-old male wild type or Ccl19-creneg×Rosa26-DTR+/− mice
were used. Each splenic FRC sample was derived by pooling lysed cells from three
independent experiments in which 2500 to 12,000 cells were sorted. In all cases,
samples were sorted at >94% purity. RNA was isolated as described60. All samples
had RIN scores of 8.7 or greater, as determined with a BioAnalyzer (Agilent).
Paired-end RNA-seq libraries were constructed from 747 pg of RNA using the
c
0
2
4
6
8
10
S
tr
om
a 
(C
D
45
– )
(1
06
 c
el
ls
 in
 s
pl
ee
n)
d e f
4.49
100 101 102 103 104 105
0
–103
103
104
105
0
–103
103
104
105
Sham 
ORX 
Sham 
8.76
ORX 
F
R
C
 (
P
D
P
N
+
C
D
31
– )
(%
 o
f C
D
45
–  
ce
lls
 in
 s
pl
ee
n)
0
2
4
6
8
10
12
14 ** *
a
S
M
A
 a
re
a
(%
 o
f P
A
LS
)
bControl
G-ARKO
F
R
C
 (
P
D
P
N
+
C
D
31
– )
(1
05
 c
el
ls
 in
 s
pl
ee
n)
0
2
4
6
8
10
12
14
Control G-ARKO
SMA IgD
CD31
100 101 102 103 104 105
CD31
P
D
P
N
P
D
P
N
0
1
2
3
4
5
*
Fig. 5 Expansion of FRCs in testosterone/AR deﬁciency. a Quantiﬁcation of smooth muscle a-actin (SMA)-stained area, expressed as percentage of peri-
arteriolar lymphoid sheath (PALS) area in control (Pgk-Cre+) and general androgen receptor knockout (G-ARKO) male mice. n= 5–6/group. b Section of
spleens from control and G-ARKO male mice, at the border of the B cell zone and PALS area. Red, SMA-positive ﬁbroblastic reticular cells (FRC); turquoise,
IgD-positive B cells. Scale bar, 30 µm. c Representative plots of PDPN+CD31–CD45– FRCs in the spleen from sham-operated and castrated (ORX) male
mice 2 weeks after surgery. d Total number of CD45– cells in spleens of castrated or sham-operated male mice. n= 15/group. e Frequency of FRC among
stromal (CD45–) cells and f total FRCs per spleen in ORX and sham-operated male mice. Bars indicate means; circles represent individual mice.*P < 0.05,
**P < 0.01 (Mann–Whitney test)
ARTICLE NATURE COMMUNICATIONS | DOI: 10.1038/s41467-018-04408-0
10 NATURE COMMUNICATIONS |  (2018) 9:2067 | DOI: 10.1038/s41467-018-04408-0 |www.nature.com/naturecommunications
SMARTer+NexteraXT Low Input RNA Kit. Libraries were then sequenced on an
Illumina HiSeq yielding, on average, 35 million read pairs (2 × 50 bp) per sample.
We used Salmon version 0.6 (ref. 61) to quantitate reads against the GENCODE M9
mouse transcript models with “--biasCorrect” enabled and the “-l IU” library type.
These data were imported into R using the tximport package62 to get gene level
expression estimates, and limma/voom63 was used for differential expression
analysis.
Splenic FRC culture in vitro. Spleens from male mice (B6SLJ; Taconic) were
dissected, minced, and enzymatically digested35. The cells were ﬁltered through a
nylon wool sieve (70 µm) and incubated overnight in α-minimal essential medium
(32571-028; Thermoﬁsher Scientiﬁc), supplemented with 10% foetal bovine serum
and 1% penicillin/streptomycin. Non-adherent cells were removed by washing with
PBS, and the attached cells were cultured for 6 days. The cells were enriched for
non-haematopoietic and non-endothelial cells by anti-CD31 and -CD45
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microbeads (#130-097-408 and #130-052-301; Miltenyi Biotec) according to the
manufacturer’s instructions. The enriched stroma was counted and plated over-
night in six-well plates at a density of 0.2 million cells per well. Before and after
enrichment, the stromal cell composition was assessed by ﬂow cytometry for CD31
(390; eBioscience), CD45.1 (A20; BD Biosciences), and podoplanin (8.1.1; BioLe-
gend). Fluorochrome-minus-one was used as control, and dead cells excluded from
analyses by positivity for 7AAD (A1310; Life Technologies). The cells were ana-
lysed on an Accuri C6 ﬂow cytometer (BD Biosciences), and the data were analysed
with FlowJo software (Tree Star).
To evaluate the effect of α-adrenergic signalling on stromal cell growth, medium
containing the α-adrenergic agonist phenylephrine hydrochloride (10−7–10−4 M;
P1250000; Sigma Aldrich) and/or the α-adrenergic antagonist phentolamine
hydrochloride (10−7–10−5 M; P7547; Sigma Aldrich) was added to the culture and
exchanged after 24 h. After 48 h, live stromal cells were counted with DAPI-
containing solution #13 in a Nucleocounter NC-3000 (Chemometec). Cell viability
was not affected by the α-adrenergic agonist/antagonist at the concentrations
shown; however, phentolamine at 10-4 M was toxic, resulting in no live cells at 48 h.
The cells were stained with anti-podoplanin antibody and analysed by ﬂow
cytometry as described above. To assess apoptosis, cells were stained with annexin
V (FITC Annexin V Apoptosis Detection Kit, 556547; BD Biosciences) after a 48-h
incubation with agonist/antagonist. Cell division was revealed by CFSE staining;
cells were stained with CFSE (CellTrace CFSE Cell Proliferation Kit, C34554;
Thermoﬁsher Scientiﬁc) according to the manufacturer’s instructions, incubated
with agonist/antagonist, and analysed by ﬂow cytometry after 48 h.
Statistical analysis. For statistical evaluations, Prism (version 5; GraphPad Soft-
ware) and SPSS (version 15.0; SPSS) were used. For mouse data, the non-
parametrical Mann–Whitney test was used for two-group comparisons, and the
Kruskal–Wallis test followed by the Mann–Whitney test was used for four-group
comparisons. In vitro data were analysed by one-way ANOVA followed by Bon-
ferroni correction. Linear regression models were used to assess differences in
serum BAFF levels between hypogonadal and eugonadal men with and without
adjustment for age and body mass index (log-transformed). No statistical methods
were used to predetermine sample size. Animals were allocated to experimental
groups by genotype or arbitrarily without formal randomization and there were no
exclusions of mice. Investigators were not formally blinded to group allocation
during the experiment. P < 0.05 (two-sided) was considered statistically signiﬁcant.
Data availability. The datasets analysed during the current study are available
from the corresponding author on reasonable request. BioSample metadata are
available in the NCBI BioSample database under accession numbers
SAMN08824665 [https://www.ncbi.nlm.nih.gov/biosample/?
term=SAMN08824665] and SAMN08824666 [https://www.ncbi.nlm.nih.gov/
biosample/?term=SAMN08824666].
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